MTOR and breast carcinoma: More than 50% of ER/PR-positive breast cancers contain alterations in at least one component of the PI3K/Akt/mTOR pathway, and these alterations drive cancer growth and also facilitate development of resistance to hormone prevention therapies [8, 9].